Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Boslego

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Antonie Van Leeuwenhoek|January 1, 1987
Gene conversion accounts for pilin structural changes and for reversible piliation "phase" changes in gonococciJ Swanson, S Bergstrom, J Boslego, et al.
The Journal of Experimental Medicine|December 1, 1988
Expression of outer membrane protein II by gonococci in experimental gonorrheaJ Swanson, O Barrera, J Sola, et al.
Antonie Van Leeuwenhoek|January 1, 1987
Analyses of the immunoaccessibility of H8 antigen and the functionality of H8 specific monoclonal antibody 10P J Hitchcock, J Boslego, K A Joiner, et al.
Vaccine|March 3, 2001
A combined liquid Hib (PRP-OMPC), hepatitis B, diphtheria, tetanus and whole-cell pertussis vaccine: controlled studies of immunogenicity and reactogenicityT Nolan, G Hogg, M A Darcy, et al.
The Journal of Infectious Diseases|July 1, 1980
Antigenic specificity of antibodies in vaginal secretions during infection with Neisseria gonorrhoeaeE C Tramont, J Ciak, J Boslego, et al.
The Journal of Infectious Diseases|July 1, 1992
Age-specific prevalence of serum antibodies to the invasion plasmid and lipopolysaccharide antigens of Shigella species in Chilean and North American populationsL L Van de Verg, D A Herrington, J Boslego, et al.
The Journal of Experimental Medicine|May 1, 1987
Gonococcal pilin variants in experimental gonorrheaJ Swanson, K Robbins, O Barrera, et al.
Antonie Van Leeuwenhoek|January 1, 1987
Human bactericidal antibody response to meningococcal outer membrane protein vaccinesW D Zollinger, J Boslego, L O Frøholm, et al.
Vaccine|June 1, 1995
Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Chilean National Committee for Meningococcal DiseaseJ Boslego, J Garcia, C Cruz, et al.
Vaccine|October 24, 2001
Large scale safety study of a liquid hexavalent vaccine (D-T-acP-IPV-PRP--T-HBs) administered at 2, 4, 6 and 12-14 months of ageJ G Liese, S Stojanov, F Berut, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Antonie Van Leeuwenhoek|January 1, 1987
Gene conversion accounts for pilin structural changes and for reversible piliation "phase" changes in gonococciJ Swanson, S Bergstrom, J Boslego, et al.
The Journal of Experimental Medicine|December 1, 1988
Expression of outer membrane protein II by gonococci in experimental gonorrheaJ Swanson, O Barrera, J Sola, et al.
Antonie Van Leeuwenhoek|January 1, 1987
Analyses of the immunoaccessibility of H8 antigen and the functionality of H8 specific monoclonal antibody 10P J Hitchcock, J Boslego, K A Joiner, et al.
Vaccine|March 3, 2001
A combined liquid Hib (PRP-OMPC), hepatitis B, diphtheria, tetanus and whole-cell pertussis vaccine: controlled studies of immunogenicity and reactogenicityT Nolan, G Hogg, M A Darcy, et al.
The Journal of Infectious Diseases|July 1, 1980
Antigenic specificity of antibodies in vaginal secretions during infection with Neisseria gonorrhoeaeE C Tramont, J Ciak, J Boslego, et al.
The Journal of Infectious Diseases|July 1, 1992
Age-specific prevalence of serum antibodies to the invasion plasmid and lipopolysaccharide antigens of Shigella species in Chilean and North American populationsL L Van de Verg, D A Herrington, J Boslego, et al.
The Journal of Experimental Medicine|May 1, 1987
Gonococcal pilin variants in experimental gonorrheaJ Swanson, K Robbins, O Barrera, et al.
Antonie Van Leeuwenhoek|January 1, 1987
Human bactericidal antibody response to meningococcal outer membrane protein vaccinesW D Zollinger, J Boslego, L O Frøholm, et al.
Vaccine|June 1, 1995
Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Chilean National Committee for Meningococcal DiseaseJ Boslego, J Garcia, C Cruz, et al.
Vaccine|October 24, 2001
Large scale safety study of a liquid hexavalent vaccine (D-T-acP-IPV-PRP--T-HBs) administered at 2, 4, 6 and 12-14 months of ageJ G Liese, S Stojanov, F Berut, et al.
Pageof 2